Go-Ahead for the Clinical Phase II Trial
Zurich, May 03, 2016. MetrioPharm AG announces the start of the clinical phase IIa trial in moderate-to-severe psoriasis for its lead molecule MP1032.
After receiving approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the clinical phase IIa study, the first study site will open next week. From that day on, psoriasis patients can be enrolled in the trial investigating safety and tolerability of MP1032 in patients.
In addition to tolerability data, parameters on the therapeutic effect of MP1032 on psoriasis will be analyzed.
"We are very happy to start a phase IIa clinical trial only few months after completing our phase I trial; the strong personal commitment of the MetrioPharm team made it possible to meet this stringent timetable.
This phase IIa study is primarily designed to confirm MP1032's excellent safety and tolerability profile observed in animals and healthy volunteers. In addition, we expect to generate first data on the therapeutic efficacy of MP1032 for the treatment of psoriasis," commented Dr. Wolfgang Brysch, CSO and President of the Board.
MetrioPharm's proprietary drug candidate MP1032 is a novel synthetic smallmolecule drug with strong anti-inflammatory properties and an excellent toxicity profile in preclinical studies. MP1032 belongs to a new class of macrophage-modulatory drugs that act on the innate immune system. MP1032 targets the molecular activation mechanisms of inflammatory macrophages. These cells drive the inflammation, pain and tissue damage in a wide range of inflammatory and auto-immune diseases such as psoriasis, rheumatoid arthritis, musculo-skeletal injuries and multiple sclerosis.
MetrioPharm is a clinical-stage drug development company with legal base in Zurich and an R&D location in Berlin. The company develops a breakthrough class of new anti-inflammatory and immunemodulating drugs against chronic inflammatory and autoimmune diseases.